Oracle's Contradiction: A Record Pipeline Meets Insider Selling and a Legendary Bear

Oracle's record cloud backlog and defense deals clash with Michael Burry's short bet and UBS's price cut, leaving investors torn.

The gap between what Oracle's order book is saying and what its stock chart is whispering has rarely been wider. On any given week, the company can announce a landmark government contract, a health-care expansion, or a deepening cloud partnership with Google — and still find itself trading below its 200-day moving average, with executives quietly cashing out and one of Wall Street's most famous skeptics loading up on bearish bets.

That tension, rather than any single headline, is the story investors are wrestling with.

The Bull Case Is Built on Billions in Contracts

The operational momentum is hard to dismiss. In early August, Oracle disclosed a $400 million task order to modernize federal HR systems through contractor CACI International, with Baker Tilly and Deloitte joining as technology partners. The same week brought an expanded Google Cloud alliance that integrates Gemini models into Fusion Applications and NetSuite, plus the addition of Baycrest Hospital in Ontario to Oracle Health's shared electronic health record rollout with Sunnybrook.

Investors rewarded the news flow: the stock jumped 9.22 percent on the health-care announcement, following a more than 8 percent pop in late July when the Gemini integration was first teased.

Those moves build on a deeper foundation. In July, Oracle secured a ten-year agreement under the U.S. Department of Defense's Enterprise Software Initiative, carrying a base value of $3.31 billion for the first five years and up to $6.99 billion if option years are exercised. The company's cloud backlog now stands at $638 billion, with infrastructure revenue growing 93 percent year over year. Oracle's CIO has pointed to at least $441 million in taxpayer savings under the defense deal.

The stock has climbed 27.59 percent from its 52-week low of €100.76, set on July 28, and added 4.30 percent over the past seven trading sessions.

Burry's Warning and a Wall Street Nudge

Into that rally stepped Michael Burry. On August 6, the investor known for betting against overextended markets opened a fresh short position in Oracle at $144.63 per share, citing growing leverage risks from off-balance-sheet obligations across the tech and cloud sectors. The timing was notable: just a day earlier, he had closed a prior put position on the stock with what he called "substantial" gains, only to immediately re-engage.

Burry's language was characteristically blunt. He described Oracle as being "in a bit of a bind" and warned that a potential collapse could become "the most expensive tragedy in a very long time." His critique extends beyond individual contracts to the structural question of how the entire AI infrastructure boom gets financed — and what happens when the bill comes due.

He isn't entirely alone in his caution. UBS trimmed its price target on Oracle from $285 to $245 on August 3, though it maintained a buy rating — a move that reads more like a compromise between enthusiasm for the deal flow and discomfort with the valuation than a full-throated endorsement.

Insider Selling Tells Its Own Story

Less noticed in the public debate is a third data point: over the past 90 days, Oracle has recorded 13 insider transactions, all of them sales, totaling roughly $132.3 million. The bulk came from planned and announced sales by Vice Chairman Jeffrey Henley.

Such sales often follow pre-arranged trading plans and shouldn't automatically be read as a vote of no confidence. But taken together, they paint a picture in which the loudest bullish messages come from outside the company, while those inside are quietly taking money off the table.

The Founder's Financial Web

Burry's skepticism also zeroes in on Oracle founder Larry Ellison's financial entanglements. Ellison holds roughly 1.158 billion shares — about 40.6 percent of all outstanding stock — and collected an estimated $579 million from the most recent quarterly dividend of $0.50 per share.

But in late July, Ellison signed an irrevocable personal guarantee of $40.4 billion for the equity financing of Paramount Skydance in its battle for Warner Bros. Discovery, pledging not to touch his Oracle share trust in the meantime. That commitment ties up capital that would otherwise be available to support the company's ambitions. It comes as Oracle has cut 21,000 jobs in a year — nearly 13 percent of its workforce, shrinking from 162,000 to 141,000 full-time employees — while pledging more than $20 billion in investments for 2026.

Where the Stock Stands

At €128.56, Oracle remains 15.53 percent below its 200-day average of €152.20, a sign that the recent recovery has slowed the medium-term downtrend without breaking it. The stock closed Friday at €127.10, up 3.12 percent over seven sessions — a tentative lifeline after a year in which it lost 41.64 percent and still sits 56.89 percent below its record high from September 10, 2025.

The next test comes with quarterly earnings on September 7, where consensus expects $1.77 in earnings per share on $19.52 billion in revenue. Whether the contract momentum or the balance-sheet concerns win out may become clearer then.

For now, neither narrative fully dominates. Oracle's operations are delivering tangible wins, while the financing architecture around its founder and the scale of its AI bets raise questions that aren't going away. Investors watching the stock would do well to track both — not just the louder one.